# Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment

> **NCT07067385** · PHASE1 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy
- Gastrointestinal Tumors

## Interventions

- **BIOLOGICAL:** Neoantigen Personalized Cancer Vaccine

## Key facts

- **NCT ID:** NCT07067385
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-07-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07067385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07067385, "Personalized mRNA Cancer Vaccine for Gastrointestinal Solid Tumor Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07067385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*